,address1,address2,city,state,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,630 5th Avenue,20th Floor,New York,NY,10111,United States,844 689 3939,https://www.anavex.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.",38,"{'maxAge': 1, 'name': 'Dr. Christopher U. Missling M.B.A., M.S., Ph.D.', 'age': 56, 'title': 'Chairman, Pres, CEO & Sec.', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 708600, 'exercisedValue': 0, 'unexercisedValue': 39571984}",7,3,8,1,4,1693526400,1672444800,86400,2,7.95,8.0,7.55,8.0299,7.95,8.0,7.55,8.0299,0.0,0.683609,-11.646154,2689932,2689932,818964,1100240,1100240,7.57,7.75,1200,900,620369856,7.44,15.24,8.1718,8.921225,0.0,0.0,USD,465552768,0.0,79363918,81951104,16878865,16536540,1690761600,1693440000,0.206,0.03194,0.33901,20.18,0.21200001,81951104,1.803,4.1985583,1664496000,1696032000,1688083200,-51649372,-0.64,-0.65,1:4,1444176000,-0.16629958,0.14113986,NMS,EQUITY,AVXL,AVXL,Anavex Life Sciences Corp.,Anavex Life Sciences Corp.,1154525400,America/New_York,EDT,a192134c-09ce-387b-bb62-3b271f6333ed,finmb_13580387,-14400000,7.57,58.0,39.0,47.75,47.0,2.0,buy,4,154817168,1.889,0,14.2,14.275,-0.21753,-0.34723,-9765258,-25979306,0.0,0.0,0.0,USD,
1,630 5th Avenue,20th Floor,New York,NY,10111,United States,844 689 3939,https://www.anavex.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.",38,"{'maxAge': 1, 'name': 'Ms. Sandra  Boenisch CPA, CPA, CGA', 'age': 41, 'title': 'Principal Financial Officer & Treasurer', 'yearBorn': 1981, 'fiscalYear': 2022, 'totalPay': 174900, 'exercisedValue': 0, 'unexercisedValue': 1436352}",7,3,8,1,4,1693526400,1672444800,86400,2,7.95,8.0,7.55,8.0299,7.95,8.0,7.55,8.0299,0.0,0.683609,-11.646154,2689932,2689932,818964,1100240,1100240,7.57,7.75,1200,900,620369856,7.44,15.24,8.1718,8.921225,0.0,0.0,USD,465552768,0.0,79363918,81951104,16878865,16536540,1690761600,1693440000,0.206,0.03194,0.33901,20.18,0.21200001,81951104,1.803,4.1985583,1664496000,1696032000,1688083200,-51649372,-0.64,-0.65,1:4,1444176000,-0.16629958,0.14113986,NMS,EQUITY,AVXL,AVXL,Anavex Life Sciences Corp.,Anavex Life Sciences Corp.,1154525400,America/New_York,EDT,a192134c-09ce-387b-bb62-3b271f6333ed,finmb_13580387,-14400000,7.57,58.0,39.0,47.75,47.0,2.0,buy,4,154817168,1.889,0,14.2,14.275,-0.21753,-0.34723,-9765258,-25979306,0.0,0.0,0.0,USD,
2,630 5th Avenue,20th Floor,New York,NY,10111,United States,844 689 3939,https://www.anavex.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.",38,"{'maxAge': 1, 'name': 'Mr. Stephan  Toutain', 'age': 56, 'title': 'Chief Operating Officer', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}",7,3,8,1,4,1693526400,1672444800,86400,2,7.95,8.0,7.55,8.0299,7.95,8.0,7.55,8.0299,0.0,0.683609,-11.646154,2689932,2689932,818964,1100240,1100240,7.57,7.75,1200,900,620369856,7.44,15.24,8.1718,8.921225,0.0,0.0,USD,465552768,0.0,79363918,81951104,16878865,16536540,1690761600,1693440000,0.206,0.03194,0.33901,20.18,0.21200001,81951104,1.803,4.1985583,1664496000,1696032000,1688083200,-51649372,-0.64,-0.65,1:4,1444176000,-0.16629958,0.14113986,NMS,EQUITY,AVXL,AVXL,Anavex Life Sciences Corp.,Anavex Life Sciences Corp.,1154525400,America/New_York,EDT,a192134c-09ce-387b-bb62-3b271f6333ed,finmb_13580387,-14400000,7.57,58.0,39.0,47.75,47.0,2.0,buy,4,154817168,1.889,0,14.2,14.275,-0.21753,-0.34723,-9765258,-25979306,0.0,0.0,0.0,USD,
3,630 5th Avenue,20th Floor,New York,NY,10111,United States,844 689 3939,https://www.anavex.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.",38,"{'maxAge': 1, 'name': 'Dr. Walter E. Kaufmann M.D.', 'title': 'Chief Scientific Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",7,3,8,1,4,1693526400,1672444800,86400,2,7.95,8.0,7.55,8.0299,7.95,8.0,7.55,8.0299,0.0,0.683609,-11.646154,2689932,2689932,818964,1100240,1100240,7.57,7.75,1200,900,620369856,7.44,15.24,8.1718,8.921225,0.0,0.0,USD,465552768,0.0,79363918,81951104,16878865,16536540,1690761600,1693440000,0.206,0.03194,0.33901,20.18,0.21200001,81951104,1.803,4.1985583,1664496000,1696032000,1688083200,-51649372,-0.64,-0.65,1:4,1444176000,-0.16629958,0.14113986,NMS,EQUITY,AVXL,AVXL,Anavex Life Sciences Corp.,Anavex Life Sciences Corp.,1154525400,America/New_York,EDT,a192134c-09ce-387b-bb62-3b271f6333ed,finmb_13580387,-14400000,7.57,58.0,39.0,47.75,47.0,2.0,buy,4,154817168,1.889,0,14.2,14.275,-0.21753,-0.34723,-9765258,-25979306,0.0,0.0,0.0,USD,
4,630 5th Avenue,20th Floor,New York,NY,10111,United States,844 689 3939,https://www.anavex.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.",38,"{'maxAge': 1, 'name': 'Clint  Tomlinson', 'title': 'VP of Corp.', 'exercisedValue': 0, 'unexercisedValue': 0}",7,3,8,1,4,1693526400,1672444800,86400,2,7.95,8.0,7.55,8.0299,7.95,8.0,7.55,8.0299,0.0,0.683609,-11.646154,2689932,2689932,818964,1100240,1100240,7.57,7.75,1200,900,620369856,7.44,15.24,8.1718,8.921225,0.0,0.0,USD,465552768,0.0,79363918,81951104,16878865,16536540,1690761600,1693440000,0.206,0.03194,0.33901,20.18,0.21200001,81951104,1.803,4.1985583,1664496000,1696032000,1688083200,-51649372,-0.64,-0.65,1:4,1444176000,-0.16629958,0.14113986,NMS,EQUITY,AVXL,AVXL,Anavex Life Sciences Corp.,Anavex Life Sciences Corp.,1154525400,America/New_York,EDT,a192134c-09ce-387b-bb62-3b271f6333ed,finmb_13580387,-14400000,7.57,58.0,39.0,47.75,47.0,2.0,buy,4,154817168,1.889,0,14.2,14.275,-0.21753,-0.34723,-9765258,-25979306,0.0,0.0,0.0,USD,
5,630 5th Avenue,20th Floor,New York,NY,10111,United States,844 689 3939,https://www.anavex.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.",38,"{'maxAge': 1, 'name': 'Dr. Adebayo  Laniyonu Ph.D.', 'title': 'Sr. VP of Nonclinical Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",7,3,8,1,4,1693526400,1672444800,86400,2,7.95,8.0,7.55,8.0299,7.95,8.0,7.55,8.0299,0.0,0.683609,-11.646154,2689932,2689932,818964,1100240,1100240,7.57,7.75,1200,900,620369856,7.44,15.24,8.1718,8.921225,0.0,0.0,USD,465552768,0.0,79363918,81951104,16878865,16536540,1690761600,1693440000,0.206,0.03194,0.33901,20.18,0.21200001,81951104,1.803,4.1985583,1664496000,1696032000,1688083200,-51649372,-0.64,-0.65,1:4,1444176000,-0.16629958,0.14113986,NMS,EQUITY,AVXL,AVXL,Anavex Life Sciences Corp.,Anavex Life Sciences Corp.,1154525400,America/New_York,EDT,a192134c-09ce-387b-bb62-3b271f6333ed,finmb_13580387,-14400000,7.57,58.0,39.0,47.75,47.0,2.0,buy,4,154817168,1.889,0,14.2,14.275,-0.21753,-0.34723,-9765258,-25979306,0.0,0.0,0.0,USD,
6,630 5th Avenue,20th Floor,New York,NY,10111,United States,844 689 3939,https://www.anavex.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.",38,"{'maxAge': 1, 'name': 'Dr. Edward R Hammond M.D., M.P.H., Ph.D.', 'title': 'Chief Medical Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",7,3,8,1,4,1693526400,1672444800,86400,2,7.95,8.0,7.55,8.0299,7.95,8.0,7.55,8.0299,0.0,0.683609,-11.646154,2689932,2689932,818964,1100240,1100240,7.57,7.75,1200,900,620369856,7.44,15.24,8.1718,8.921225,0.0,0.0,USD,465552768,0.0,79363918,81951104,16878865,16536540,1690761600,1693440000,0.206,0.03194,0.33901,20.18,0.21200001,81951104,1.803,4.1985583,1664496000,1696032000,1688083200,-51649372,-0.64,-0.65,1:4,1444176000,-0.16629958,0.14113986,NMS,EQUITY,AVXL,AVXL,Anavex Life Sciences Corp.,Anavex Life Sciences Corp.,1154525400,America/New_York,EDT,a192134c-09ce-387b-bb62-3b271f6333ed,finmb_13580387,-14400000,7.57,58.0,39.0,47.75,47.0,2.0,buy,4,154817168,1.889,0,14.2,14.275,-0.21753,-0.34723,-9765258,-25979306,0.0,0.0,0.0,USD,
7,630 5th Avenue,20th Floor,New York,NY,10111,United States,844 689 3939,https://www.anavex.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.",38,"{'maxAge': 1, 'name': 'Dr. Kun  Jin Ph.D.', 'title': 'Head of Biostatistics', 'exercisedValue': 0, 'unexercisedValue': 0}",7,3,8,1,4,1693526400,1672444800,86400,2,7.95,8.0,7.55,8.0299,7.95,8.0,7.55,8.0299,0.0,0.683609,-11.646154,2689932,2689932,818964,1100240,1100240,7.57,7.75,1200,900,620369856,7.44,15.24,8.1718,8.921225,0.0,0.0,USD,465552768,0.0,79363918,81951104,16878865,16536540,1690761600,1693440000,0.206,0.03194,0.33901,20.18,0.21200001,81951104,1.803,4.1985583,1664496000,1696032000,1688083200,-51649372,-0.64,-0.65,1:4,1444176000,-0.16629958,0.14113986,NMS,EQUITY,AVXL,AVXL,Anavex Life Sciences Corp.,Anavex Life Sciences Corp.,1154525400,America/New_York,EDT,a192134c-09ce-387b-bb62-3b271f6333ed,finmb_13580387,-14400000,7.57,58.0,39.0,47.75,47.0,2.0,buy,4,154817168,1.889,0,14.2,14.275,-0.21753,-0.34723,-9765258,-25979306,0.0,0.0,0.0,USD,
